Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche's Lunsumio combination hits Phase III PFS goal in 2L+ follicular lymphoma

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

Roche's Phase III CELESTIMO trial showed that mosunetuzumab (Lunsumio) combined with lenalidomide met its primary progression-free survival endpoint in relapsed or refractory follicular lymphoma, supporting full FDA and EU approvals for second-line or later treatment.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You face a market opening as Roche aims to convert accelerated approval to full clearance for Lunsumio in earlier follicular lymphoma lines. This shift invites a competitive threat from Roche against current bispecific providers like Genmab and AbbVie at a new treatment stage.

◆ Coverage

2 sources · 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfollicular-lymphomaphase-iiibispecific-antibodydrug-approvalimmunotherapy